Official collaboration between PredictCan Biotechnologies and PRADO, Preclinical Research and Development Organization to develop alternative solutions to animal testing.

Animal testing plays a critical role in gaining important knowledge needed to thoroughly evaluate the products towards reducing the health risks and sufferings to human and animals. The current regulatory framework of various countries and FDA permits, encourages, and supports the use of new alternative methods to animal testing that produce scientifically valid data and meet the regulatory requirements.

PredictCan Biotechnologies and PRADO collaborate to develop models for idiosyncratic drug-induced liver injury (iDILI) as an initial step.

PRADO is a Preclinical Research and Development Organization Private Limited, based in Pune India. PRADO is one of the emerging, global, independent market leaders in providing preclinical services. The company supports Pharmaceutical, Biopharma, Biotech, Medical Devices, Pesticides and Agrochemicals, Food, Vaccine, and Animal Health Industries by providing high quality preclinical services to meet their regulatory requirements.

PredictCan Biotechnologies is a French biotech based in Montpellier France. PredictCan has long-lasting expertise in translational research and precision medicine to deliver innovative tools for cancer detection and treatment. The company owns a unique cell educating technology to generate animal-free and non-invasive subject-centric models for iDILI detection and drug efficacy testing. We provide cutting-edge solutions to patients, clinicians, and pharmaceutical industries supporting their combat against diseases.

PredictCan Biotechnologies CEO, Hong Tuan DUONG said that we have developed a novel technology, which offers unique, individual-centric model to analyze iDILI risk. So, this model will reduce the testing time and will be economical.

PRADO CEO, Dr. Pralhad Wangikar said that we are excited to use non-animal and human-relevant methods. Various models are being tested as an alternative to animal testing however, the model developed by PredictCan Biotechnologies is innovative and we look forward that this model will help in predicting the human biology more accurately and can complement, or in some cases, replace traditional animal models.

More Articles

Official collaboration between PredictCan Biotechnologies and PRADO, Preclinical Research and Development Organization to develop alternative solutions to animal testing.

Animal testing plays a critical role in gaining important knowledge needed to thoroughly evaluate the products towards reducing the health risks and sufferings to human and animals. The current regulatory framework of various countries and FDA permits, encourages, and supports the use of new alternative methods to animal testing that

Read More »

PredictCan members attended the EUROTOX 2024 in Copenhagen

Our CEO Dr Hong Tuan DUONG, discussed the use of individual-centric spheroid model to decipher the initiating-mechanism of immune mediated idiosyncratic drug-induced liver injury by presenting the poster “Dissecting the idiosyncratic drug-induced liver injury (iDILI)-initiating mechanism using the individual-centric model: the role of the innate immune response” While Dr Sara

Read More »

PredictCan is part of the North American 3Rs collaborative as a bronze-level initiative member

We are pleased to announce that PredictCan Biotechnologies joined the North American 3Rs collaborative as a bronze-level initiative member. The 3Rs collaborative is a non-profit organization that facilitates collaborative opportunities between academics, pharmaceutical companies, contract research organizations, government organizations, and regulatory agents to refine, reduce, and replace animals in research.

Read More »

New scientific publication in Front. Pharmacol., 2024

We are pleased to announce that our original research article on the capability of individual-centric spheroid model to detect immune-mediated idiosyncratic DILI at therapeutic doses has just been published in Frontiers in Pharmacology, section Predictive Toxicology. « Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury:

Read More »

Pr Jean-François DUFOUR as a new member of PredictCan’s Scientific Advisory Board

PredictCan Biotechnologies is pleased to announce the appointment of Professor Jean-François DUFOUR to its Scientific Advisory Board. Professor DUFOUR is a world-leading hepatologist focusing on Metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC).  He published more than 350 scientific publications and is an associate editor of GUT. Professor DUFOUR is

Read More »